Inflammatory markers and physical function among older adults with knee osteoarthritis

Journal of Rheumatology

Volumn 31, Issue 10, 2004, Pages 2027-2031

  Penninx, Brenda W J H ^a   Abbas, Haider ^a   Ambrosius, Walter ^b   Nicklas, Barbara J ^a,b   Davis, Cralen ^b   Messier, Stephen P ^c   Pahor, Marco ^a  

^a Sticht Center on Aging   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c WAKE FOREST UNIVERSITY   (United States)

Author keywords

Inflammation; Osteoarthritis; Physical function; Soluble tumor necrosis factor receptors

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADULT; AGE; ARTICLE; BODY MASS; COMORBIDITY; DISABILITY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXERCISE; FEMALE; GENDER; HUMAN; INFLAMMATION; KNEE OSTEOARTHRITIS; KNEE RADIOGRAPHY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NUTRITION; OBESITY; PAIN; PRIORITY JOURNAL; RACE; RATING SCALE; RIGIDITY; SELF REPORT; WALKING SPEED; WESTERN ONTARIO AND MCMASTER UNIVERSITY OSTEOARTHRITIS INDEX;

ACTIVITIES OF DAILY LIVING; ADULT; AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; DIET; DISABILITY EVALUATION; EXERCISE THERAPY; HUMANS; INTERLEUKIN-6; MIDDLE AGED; OBESITY; OSTEOARTHRITIS, KNEE; QUESTIONNAIRES; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA; WALKING;

EID: 5044235574     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-9.
2. Tracy RP, Lemaitre RN, Psaty BM, et al. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol 1997;17:1121-7.
3. Ferrucci L, Penninx BW, Volpato S, et al. Change in muscle strength explains accelerated decline of physical function in older women with high interleukin-6 serum levels. J Am Geriatr Soc 2002;50:1947-54.
4. Ferrucci L, Harris TB, Guralnik JM, et al. Serum IL-6 level and the development of disability in older persons. J Am Geriatr Soc 1999;47:639-46.
5. Penninx BW, Kritchevsky SB, Newman AB, et al. Inflammatory markers and incident mobility limitation in the elderly. J Am Geriatr Soc 2004;52:1105-13.
6. Beckham JC, Caldwell DS, Peterson BL, et al. Disease severity in rheumatoid arthritis: relationships of plasma tumor necrosis factor-alpha, soluble interleukin 2-receptor, soluble CD4/CD8 ratio, neopterin, and fibrin D-dimer to traditional severity and functional measures. J Clin Immunol 1992;12:353-61.
7. Saxne T, Lindell M, Mansson B, Petersson IF, Heinegard D. Inflammation is a feature of the disease process in early knee joint osteoarthritis. Rheumatology Oxford 2003;42:903-4.
8. Pelletier JP, Martel-Pelletier J, Abramson SB. Osteoarthritis, an inflammatory disease: potential implication for the selection of new therapeutic targets. Arthritis Rheum 2001;44:1237-47.
9. Smith MD, Triantafillou S, Parker A, Youssef PP, Coleman M. Synovial membrane inflammation and cytokine production in patients with early osteoarthritis. J Rheumatol 1997;24:365-71.
10. Cohen HJ, Pieper CF, Harris T, Rao KM, Currie MS. The association of plasma IL-6 levels with functional disability in community-dwelling elderly. J Gerontol A Biol Sci Med Sci 1997;52:M201-8.
11. Spector TD, Hart DJ, Nandra D, et al. Low-level increases in serum C-reactive protein are present in early osteoarthritis of the knee and predict progressive disease. Arthritis Rheum 1997;40:723-7.
12. Goldring MB. Osteoarthritis and cartilage: the role of cytokines. Curr Rheumatol Rep 2000;2:459-65.
13. Spinas GA, Keller U, Brockhaus M. Release of soluble receptors for tumor necrosis factor (TNF) in relation to circulating TNF during experimental endotoxinemia. J Clin Invest 1992;90:533-6.
14. Van Zee KJ, Kohno T, Fischer E, Rock CS, Moldawer LL, Lowry SF. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc Natl Acad Sci USA 1992;89:4845-9.
15. Honda M, Yamamoto S, Cheng M, et al. Human soluble IL-6 receptor: its detection and enhanced release by HIV infection. J Immunol 1992;148:2175-80.
16. Aderka D, Engelmann H, Shemer-Avni Y, et al. Variation in serum levels of the soluble TNF receptors among healthy individuals. Lymphokine Cytokine Res 1992;11:157-9.
17. Schroder J, Stuber F, Gallati H, Schade FU, Kremer B. Pattern of soluble TNF receptors I and II in sepsis. Infection 1995;23:143-8.
18. Sharif M, Shepstone L, Elson CJ, Dieppe PA, Kirwan JR. Increased serum C reactive protein may reflect events that precede radiographic progression in osteoarthritis of the knee. Ann Rheum Dis 2000;59:71-4.
19. Miller GD, Rejeski WJ, Williamson JD, et al. The Arthritis, Diet and Activity Promotion Trial (ADAPT): design, rationale, and baseline results. Control Clin Trials 2003;24:462-80.
20. Rejeski WJ, Focht BC, Messier SP, Morgan T, Pahor M, Penninx B. Obese, older adults with knee osteoarthritis: weight loss, exercise, and quality of life. Health Psychol 2002;21:419-26.
21. Bellamy N. WOMAC: a 20-year experiential review of a patient-centered self-reported health status questionnaire. J Rheumatol 2002;29:2473-6.
22. Rejeski WJ, Ettinger WH Jr, Schumaker S, James P, Burns R, Elam JT. Assessing performance-related disability in patients with knee osteoarthritis. Osteoarthritis Cartilage 1995;3:157-67.
23. Altman R, Asch E, Bloch D, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum 1986;29:1039-49.
24. Westacott CI, Sharif M. Cytokines in osteoarthritis: mediators or markers of joint destruction? Semin Arthritis Rheum 1996;25:254-72.
25. Uson J, Balsa A, Pascual-Salcedo D, et al. Soluble interleukin 6 (IL-6) receptor and IL-6 levels in serum and synovial fluid of patients with different arthropathies. J Rheumatol 1997;24:2069-75.
26. Garnero P, Piperno M, Gineyts E, Christgau S, Delmas PD, Vignon E. Cross sectional evaluation of biochemical markers of bone, cartilage, and synovial tissue metabolism in patients with knee osteoarthritis: relations with disease activity and joint damage. Ann Rheum Dis 2001;60:619-26.
27. Wolfe F. The C-reactive protein but not erythrocyte sedimentation rate is associated with clinical severity in patients with osteoarthritis of the knee or hip. J Rheumatol 1997;24:1486-8.
28. Otterness IG, Weiner E, Swindell AC, Zimmerer RO, Ionescu M, Poole AR. An analysis of 14 molecular markers for monitoring osteoarthritis. Relationship of the markers to clinical end-points. Osteoarthritis Cartilage 2001;9:224-31.
29. Martel-Pelletier J, Alaaeddine N, Pelletier JP. Cytokines and their role in the pathophysiology of osteoarthritis. Front Biosci 1999;4:D694-703.
30. Alaaeddine N, DiBattista JA, Pelletier JP, et al. Osteoarthritic synovial fibroblasts possess an increased level of tumor necrosis factor-receptor 55 (TNF-R55) that mediates biological activation by TNF-alpha. J Rheumatol 1997;24:1985-94.
31. Webb GR, Westacott CI, Elson CJ. Chondrocyte tumor necrosis factor receptors and focal loss of cartilage in osteoarthritis. Osteoarthritis Cartilage 1997;5:427-37.
32. Westacott CI, Barakat AF, Wood L, et al. Tumor necrosis factor alpha can contribute to focal loss of cartilage in osteoarthritis. Osteoarthritis Cartilage 2000;8:213-21,
33. Otterness IG, Swindell AC, Zimmerer RO, Poole AR, Ionescu M, Weiner E. An analysis of 14 molecular markers for monitoring osteoarthritis: segregation of the markers into clusters and distinguishing osteoarthritis at baseline. Osteoarthritis Cartilage 2000;8:180-5.